Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Amortization of Deferred Charges (2020 - 2021)

Apellis Pharmaceuticals (APLS) has 2 years of Amortization of Deferred Charges data on record, last reported at $3000.0 in Q4 2021.

  • For Q4 2021, Amortization of Deferred Charges fell 76.92% year-over-year to $3000.0; the TTM value through Dec 2021 reached $113000.0, down 49.1%, while the annual FY2021 figure was $113000.0, 49.1% down from the prior year.
  • Amortization of Deferred Charges reached $3000.0 in Q4 2021 per APLS's latest filing, up from -$8000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $125000.0 in Q3 2020 and bottomed at -$8000.0 in Q3 2021.